Argos Therapeutics (ARGS) Misses Q3 EPS by 10c

Argos Therapeutics (NASDAQ: ARGS) reported Q3 EPS of ($0.83), $0.10 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $303 thousand versus the consensus estimate of $670 thousand.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• L3Harris CEO steps down amid conduct review, shares drop
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c